You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

JAK Kinase Inhibitors

Showing 1 - 25 of 6,719
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Janus Kinase Inhibitors Vs Tumor Necrosis Factor Inhibitors in

Not yet recruiting
  • Rheumatoid Arthritis
  • Observation
  • (no location specified)
Oct 8, 2022

Diabetes, Type 1 Trial (Abrocitinib 200 MG Oral Tablet, Ritlecitinib, Placebo)

Not yet recruiting
  • Diabetes Mellitus, Type 1
  • Abrocitinib 200 MG Oral Tablet
  • +2 more
  • (no location specified)
Feb 21, 2023

Alopecia Areata Trial in Sohag (Janus Kinase 1 and 2)

Recruiting
  • Alopecia Areata
  • Janus Kinase 1 and 2
  • Sohag, Egypt
    Sohag University hospitals
May 12, 2023

JAK Inhibition in Ulcerative Colitis

Not yet recruiting
  • Analyzing Immune Composition Changes Upon JAK Inhibitor Treatment of Ulcerative Colitis Patients
  • JAK inhibitor treatment
  • (no location specified)
Jul 11, 2022

Toxic Epidermal Necrolysis Trial in Fuzhou (Abrocitinib)

Recruiting
  • Toxic Epidermal Necrolysis
  • Fuzhou, Fujian, China
    Department of Dermatology, the First Affiliated Hospital of Fuji
Oct 31, 2023

Rheumatoid Arthritis Trial ("apigenin" and "glycyrrhizin", "glycyrrhizin" and "boswellic acid", "")

Not yet recruiting
  • Rheumatoid Arthritis
  • "apigenin" and "glycyrrhizin"
  • +2 more
  • (no location specified)
Mar 27, 2023

Abatacept, Treatment Compliance, Rheumatoid Arthritis Trial in Hangzhou (Janus Kinase Inhibitor, Abatacept)

Recruiting
  • Abatacept
  • +2 more
  • Hangzhou, Zhejiang, China
    Zhejiang Provincial People's Hospital
Jul 5, 2022

Inpatient COVID-19 Treatments

Active, not recruiting
  • COVID-19
  • Initiation of IL6Ri (tocilizumab or sarilumab) versus JAKi (baricitinib or tofacitinib) added to systemic corticosteroids of interest (CSI)
  • New York, New York
    Aetion, Inc.
Jan 12, 2023

Granuloma Annulare Trial in New Haven (Abrocitinib 200 mg)

Not yet recruiting
  • Granuloma Annulare
  • Abrocitinib 200 mg
  • New Haven, Connecticut
    Yale University
Dec 19, 2022

Cancer Trial in Changsha (Protein Kinase Inhibitor)

Recruiting
  • Cancer
  • Protein Kinase Inhibitor
  • Changsha, Hunan, China
    Central South University
Jun 23, 2022

Tyrosine Kinase Inhibitors, Chronic Myeloid Leukemia Trial in Poitiers (treatment of TKI in CML)

Not yet recruiting
  • Tyrosine Kinase Inhibitors
  • Chronic Myeloid Leukemia
  • treatment of TKI in CML
  • Poitiers, France
    Chu Poitiers
Feb 21, 2023

Inhibitors of Jak Kinases in Patients With Rheumatoid Arthritis.

Recruiting
  • Arthritis, Rheumatoid
    • Sevilla, Spain
      Hospital Universitario Virgen macarena
    Nov 15, 2021

    Cyclin-dependent Kinase 4/6 Inhibitors on Body Composition in

    Recruiting
    • Breast Cancer
    • CT scans
    • DEXA scan
    • Bronx, New York
      Montefiore Medical Center
    Jan 6, 2023

    Breast Cancer Stage IV Trial in Mansoura (comparing both arms as regard the objective response rate, toxicity profile, quality

    Recruiting
    • Breast Cancer Stage IV
    • comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival
    • Mansoura, Dakahlia, Egypt
      Oncology center mansoura university
    Jan 1, 2023

    Idiopathic Inflammatory Myopathies Trial in Beijing (tofacitinib)

    Recruiting
    • Idiopathic Inflammatory Myopathies
    • Beijing, Beijing, China
      Department of Rheumatology and Immunology, Peking University Peo
    Oct 9, 2022

    JAK Inhibitors in Systemic Sclerosis-associated Interstitial

    Recruiting
    • Systemic Sclerosis
    • Interstitial Lung Disease
      • Vandœuvre-lès-Nancy, Grand Est, France
        CHU Nancy
      Jan 19, 2022

      Sarcoidosis Trial in New Haven (Abrocitinib 200 mg)

      Not yet recruiting
      • Sarcoidosis
      • Abrocitinib 200 mg
      • New Haven, Connecticut
        Yale University
      Jan 24, 2023

      Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission, Minimal Residual

      Terminated
      • Chronic Myelogenous Leukemia, BCR-ABL1 Positive
      • +3 more
      • Houston, Texas
        M D Anderson Cancer Center
      Dec 1, 2020

      Rheumatoid Arthritis, Drug Use Trial in Hong Kong (biologic/targeted therapy)

      Not yet recruiting
      • Rheumatoid Arthritis
      • Drug Use
      • biologic/targeted therapy
      • Hong Kong, China
        Department of Medicine, Tuen Mun Hospital
      Jan 5, 2022

      Liver Transplant; Complications, Hepatocarcinoma, Recurrent Osteosarcoma Trial in Beijing (multi-kinase inhibitors in

      Not yet recruiting
      • Liver Transplant; Complications
      • +3 more
      • multi-kinase inhibitors in combination with bevacizumab
      • Beijing, Beijing, China
        Chinese Academy of Medical Sciences & Peking Union Medical Colle
      Sep 11, 2023

      Myelofibrosis Trial in Paris (Ruxolotinib)

      Completed
      • Myelofibrosis
      • Paris, France
        ROBIN
      Jul 26, 2022

      Rheumatoid Arthritis Trial in Montpellier (Blood sample analysis of patients treated as standard care)

      Recruiting
      • Rheumatoid Arthritis
      • Blood sample analysis of patients treated as standard care
      • Montpellier, France
        University Hospital of Montpellier
      Jan 12, 2022

      Skin Health and Quality of Life in Patients Receiving

      Not yet recruiting
      • Lung Cancer
      • +7 more
      • EQ-5D-5L questionnaire
      • +2 more
      • Roma, Italy
        Roberto Iacovelli
      May 17, 2023

      Immunoclassification, Psoriasis Trial in Hangzhou (adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors,

      Recruiting
      • Immunoclassification
      • Psoriasis
      • adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate
      • Hangzhou, Zhejiang, China
        2nd Affiliated Hospital, School of Medicine, Zhejiang University
      Aug 16, 2022

      B-cell Malignancies Undergoing Treatment With Bruton Tyrosine

      Not yet recruiting
      • Chronic Lymphocytic Leukemia
      • +4 more
      • Non-Interventional Study
      • Rochester, Minnesota
        Mayo Clinic in Rochester
      Nov 22, 2023